Pharmaco-utilisation and related costs of drugs used to treat schizophrenia and bipolar disorder in italy: The ibis study

BMC Psychiatry

Volumn 14, Issue 1, 2014, Pages

  Esposti, Luca Degli ^a   Sangiorgi, Diego ^a   Mencacci, Claudio ^b   Spina, Edoardo ^c   Pasina, Carlotta ^d   Alacqua, Marianna ^d   La Tour, Flore ^d  

^a Economics and Outcomes Research   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Antipsychotics; Bipolar disorder; Cost of illness; Pharmaco utilisation; Real world practice; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; HALOPERIDOL; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; CONTROLLED STUDY; COST OF ILLNESS; DRUG COST; DRUG UTILIZATION; FEMALE; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; ITALY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; OBSERVATIONAL STUDY; PERSONALIZED MEDICINE; REIMBURSEMENT; RETROSPECTIVE STUDY; SCHIZOPHRENIA; CLINICAL TRIAL; ECONOMICS; FACTUAL DATABASE; HEALTH SERVICE; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COHORT STUDIES; COST OF ILLNESS; DATABASES, FACTUAL; DRUG COSTS; DRUG UTILIZATION; FEMALE; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; ITALY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84988584748     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-014-0282-z     Document Type: Article

References (42)

1. Khan A, Faucett J, Morrison S, Brown WA: Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/hyperactivity disorder participating in psychopharmacology clinical trials. JAMA Psychiatry 2013, 70:1091-1099.
2. Laursen TM, Munk-Olsen T, Gasse C: Chronic somatic comorbidity and excess mortality due to natural causes in persons with schizophrenia or bipolar affective disorder. PLoS ONE 2011, 6:e24597.
3. Lavelle M, Healey PGT, McCabe R: Is nonverbal communication disrupted in interactions involving patients with schizophrenia? Schizophr Bull 2013, 39:1150-1158.
4. Saha S, Chant D, Welham J, McGrath J: A systematic review of the prevalence of schizophrenia. PLoS Med 2005, 2:e141.
5. Foster RH, Goa KL: Risperidone. A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1998, 14:97-133.
6. World Health Organization: The global burden of disease: 2004 update. [http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/]
7. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, Ladea M, Medina-Mora ME, Ono Y, Posada-Villa J, Sagar R, Wells JE, Zarkov Z: Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011, 68:241-251.
8. Tondo L, Isacsson G, Baldessarini R: Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs 2003, 17:491-511.
9. Verdoux H, Tournier M, Begaud B: Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 2010, 121:4-10.
10. National Institute for Clinical Excellence: Schizophrenia. Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (updated edition). [http://guidance.nice.org.uk/CG82]
11. National Institute of Clinical Excellence: Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. [http://guidance.nice.org.uk/CG38/Guidance/pdf/English]
12. American Psychiatric Association: Practice guideline for the treatment of patients with bipolar disorder. [http://psychiatryonline.org/content.aspx? bookid=28§ionid=1669577]
13. American Psychiatric Association: Practice guideline for the treatment of patients with schizophrenia second edition. [http://psychiatryonline.org/ content.aspx?bookid=28§ionid=1665359]
14. Preti A, Rucci P, Gigantesco A, Santone G, Picardi A, Miglio R, de Girolamo G: Patterns of care in patients discharged from acute psychiatric inpatient facilities: a national survey in Italy. Soc Psychiatry Psychiatr Epidemiol 2009, 44:767-776.
15. Kane JM, Correll CU: Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 2010, 71:1115-1124.
16. Sobel S: Effective personalized strategies for treating bipolar disorder. [http://www.psychiatrictimes.com/bipolar-disorder/effective-personalizedstrategies-treating-bipolar-disorder?pageNumber=2]
17. Gaebel W, Riesbeck M, Wobrock T: Schizophrenia guidelines across theworld: a selective review and comparison. Int Rev Psychiatry 2011, 23:379-387.
18. Nivoli AM, Colom F, Murru A, Pacchiarotti I, Castro-Loli P, Gonzalez-Pinto A, Fountoulakis KN, Vieta E: New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord 2011, 129:14-26.
19. Nivoli AM, Murru A, Goikolea JM, Crespo JM, Montes JM, Gonzalez-Pinto A, Garcia-Portilla P, Bobes J, Saiz-Ruiz J, Vieta E: New treatment guidelines for acute bipolar mania: a critical review. J Affect Disorrd 2012, 140:125-141.
20. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O'Donovan C, Macqueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013, 15:1-44.
21. Goodwin GM: Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009, 23:346-388.
22. Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS: Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry 2005, 187:248-255.
23. Gualano MR, Bert F, Mannocci A, La Torre G, Zeppegno P, Siliquini R: Consumption of antidepressants in Italy: recent trends and their significance for public health. Psychiatr Serv 2014, [Epub ahead of print].
24. Trifirò G, Italiano D, Alibrandi A, Sini G, Ferrajolo C, Capuano A, Spina E, Rossi A: Effects of L'Aquila earthquake on the prescribing pattern of antidepressant and antipsychotic drugs. Int J Clin Pharm 2013, 35(6):1053-1062.
25. Weiden PJ, Kozma C, Grogg A, Locklear J: Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004, 55:886-891.
26. Vieta E, Phillips ML: Deconstructing bipolar disorder: a critical review of its diagnostic validity and a proposal for DSM-V and ICD-11. Schizophr Bull 2007, 33:886-892.
27. Fountoulakis KN, Vieta E, Siamouli M, Valenti M, Magiria S, Oral T, Fresno D, Giannakopoulos P, Kaprinis GS: Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder. Ann Gen Psychiatry 2007, 6:27.
28. Black N: Developing high quality clinical databases. BMJ 1997, 315:381-382.
29. Black N, Payne M: Improving the use of clinical databases. BMJ 2002, 324:1194.
30. Hartzema AG, Racoosin JA, MaCurdy TE, Gibbs JM, Kelman JA: Utilizing Medicare claims data for real-time drug safety evaluations:is it feasible? Pharmacoepidemiol Drug Saf 2011, 20:684-688.
31. Mitchell JB, Bubolz T, Paul JE, Pashos CL, Escarce JJ, Muhlbaier LH, Wiesman JM, Young WW, Epstein RS, Javitt JC: Using Medicare claims for outcomes research. Med Care 1994, 32(7 Suppl):JS38-JS51.
32. Quam L, Ellis LB, Venus P, Clouse J, Taylor CG, Leatherman S: Using claims data for epidemiologic research. The concordance of claims-based criteria with the medical record and patient survey for identifying a hypertensive population. Med Care 1993, 31:498-507.
33. Riley GF: Administrative and claims records as sources of health care cost data. Med Care 2009, 47(7 Suppl 1):S51-S55.
34. Birnbaum HG, Cremieux PY, Greenberg PE, LeLorier J, Ostrander JA, Venditti L: Using healthcare claims data for outcomes research and pharmacoeconomic analyses. Pharmacoeconomics 1999, 16:1-8.
35. Motheral BR, Fairman KA: The use of claims databases for outcomes research: rationale, challenges, and strategies. Clin Ther 1997, 19:346-366.
36. Locklear JC, Alemayehu B, Brody RS, Chavoshi S, Tunceli O, Kern D, Earley WR: Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release of immediate release quetiapine fumarate using US healthcare administrative claims data. Clin Ther 2013, 35:1923-1932.
37. Kleine-Budde K, Touil E, Moock J, Bramesfield A, Kawohl W, Rössler W: Cost of illness for bipolar disorder: a systematic review of the economic burden. Bipolar Disord 2014, 16:337-353.
38. Fitch K, Iwasaki K, Villa KF: Resource utilization and cost in a commercially insured population with schizophrenia. Am Health Drug Benefits 2014, 7:18-26.
39. Goren JL, Meterko M, Williams S, Young GJ, Baker E, Chou C-H, Kilbourne AM, Bauer MS: Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. Psychiatr Serv 2013, 64:527-533.
40. Al Jurdi RK, Schulberg HC, Greenberg RL, Kunik ME, Gildengers A, Sajatovic M, Mulsant BH, Young RC, GERI-BD Study Group: Characteristics associated with inpatient versus outpatient status in older adults with bipolar disorder. J Geriatr Psychiatry Neurol 2012, 25:62-68.
41. Fajutrao L, Locklear J, Priaulx J, Heyes A: A systematic review of the evidence of the burden of bipolar disorder in Europe. Clin Pract Epidemiol Ment Health 2009, 5:3.
42. Das Gupta R, Guest JF: Annual cost of bipolar disorder to UK society. Br J Psychiatry 2002, 180:227-233.